IRIS
BARCHIESI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.249
EU - Europa 3.549
AS - Asia 1.539
SA - Sud America 155
AF - Africa 74
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 2
Totale 11.575
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.217
UA - Ucraina 770
IE - Irlanda 457
RU - Federazione Russa 449
TR - Turchia 430
SG - Singapore 412
IT - Italia 402
SE - Svezia 369
DE - Germania 343
DK - Danimarca 283
HK - Hong Kong 249
CN - Cina 219
FI - Finlandia 168
KR - Corea 152
BR - Brasile 139
GB - Regno Unito 137
FR - Francia 115
CI - Costa d'Avorio 57
IN - India 26
IR - Iran 24
CA - Canada 19
BE - Belgio 15
NL - Olanda 12
MX - Messico 10
AT - Austria 8
EC - Ecuador 7
BA - Bosnia-Erzegovina 6
EU - Europa 6
MA - Marocco 5
PK - Pakistan 4
UZ - Uzbekistan 4
AR - Argentina 3
BD - Bangladesh 3
PL - Polonia 3
ZA - Sudafrica 3
AU - Australia 2
CM - Camerun 2
EG - Egitto 2
ID - Indonesia 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MD - Moldavia 2
PE - Perù 2
VE - Venezuela 2
A1 - Anonimo 1
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
ES - Italia 1
ET - Etiopia 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
IQ - Iraq 1
JM - Giamaica 1
JP - Giappone 1
KH - Cambogia 1
KW - Kuwait 1
LT - Lituania 1
NP - Nepal 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
TN - Tunisia 1
TW - Taiwan 1
VN - Vietnam 1
Totale 11.575
Salva come PNG Salva come JPEG
Città #
Jacksonville 794
Fairfield 742
Chandler 537
Dublin 452
Boardman 420
Ashburn 357
Wilmington 313
Woodbridge 303
Seattle 252
Houston 245
Hong Kong 244
Des Moines 242
Cambridge 241
New York 208
Ann Arbor 193
Singapore 189
Lawrence 173
Princeton 173
San Mateo 172
Moscow 108
Turin 103
San Diego 97
Abidjan 57
Centro 51
Redmond 41
The Dalles 40
Beijing 32
London 24
Shanghai 23
Helsinki 21
Ancona 19
Los Angeles 18
Norwalk 18
Washington 18
Marche 16
Ottawa 16
Nuremberg 15
Brussels 14
Guangzhou 14
Kilburn 13
Pune 12
Wuhan 12
Bologna 9
Dallas 9
Izmir 8
Milan 8
Bari 7
São Paulo 7
Falls Church 6
Ferrara 6
Rome 6
Sarajevo 6
Andover 5
Brasília 5
Jiaxing 5
Porto Alegre 5
Prescot 5
San Severino Marche 5
Wuxi 5
Acton 4
Auburn Hills 4
Chiswick 4
Falconara Marittima 4
Hanover 4
Jinhua 4
Munich 4
Paris 4
Pesaro 4
Rio de Janeiro 4
Seoul 4
Shenzhen 4
Tashkent 4
Vienna 4
Appignano 3
Belo Horizonte 3
Cingoli 3
Curitiba 3
Delhi 3
Fayetteville 3
Guayaquil 3
Heze 3
Hounslow 3
Islington 3
Macerata 3
Mexico City 3
Mountain View 3
Nanjing 3
Naples 3
Porto 3
Squinzano 3
Yiwu 3
Amsterdam 2
Arco 2
Betim 2
Bhopal 2
Bishkek 2
Blumenau 2
Caruaru 2
Cava De' Tirreni 2
Central 2
Totale 7.267
Salva come PNG Salva come JPEG
Nome #
Antimicrobial Resistance: A Challenge for the Future 175
Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases 122
Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection 114
Candida guilliermondii fungemia in patients with hematologic malignancies. 113
Trichosporon beigelii fungaemia in an AIDS patient. 110
Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014 110
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. 109
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU 109
Antimicrobial activity of polycationic peptides 104
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. 104
Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. 103
Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature 102
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes 100
In-vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity. 99
In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp. 98
Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals 98
Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey 98
Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. 95
Sequential therapy with caspofungin and fluconazole for Candida albicans infection. 95
Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from the oral cavities of aids patients. 95
Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry 94
An (Italian) proposal for a comprehensive approach to infections across the surgical pathway 93
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. 92
High rate of ceftobiprole resistance among clinical methicillin-resistant Staphylococcus aureus isolates from a hospital in central Italy 92
Characterisation of candidemia in patients with recent surgery: A 7-year experience 91
Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients 90
Epidemiology and microbiology of surgical wound infections. 88
Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy 88
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. 87
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 87
Analysis of antibody response to Cryptococcus neoformans in five patients with AIDS and cryptococcosis by immunoblotting. 87
In-vitro activity of rifabutin and albendazolo singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 86
Candidemia in the elderly: What does it change? 86
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). 85
In vitro activities of voriconazole in combination with other three antifungal agents against Candida glabrata 84
Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata 84
In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. 83
Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi. 82
In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. 81
Reply to Ma et al.: Osteomyelitis caused by aspergillus species 80
Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy 79
Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates. 78
Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection. 78
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex 78
Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years 76
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. 76
Aspergillus spp invasive external otitis: favourable outcome with a medical approach 75
Candidemia in Internal Medicine: Facing the New Challenge 75
Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot 74
Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. 74
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates 74
Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards 74
Osteomyelitis caused by Aspergillusspecies: a review of 310 reported cases 73
In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes 73
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 73
Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines. 73
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 73
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. 72
Acute histoplasmosis in immunocompetent travelers: a systematic review of literature 71
ELECTROPHORETIC KARYOTYPING AND TRIAZOLE SUSCEPTIBILITY OF CANDIDA GLABRATA CLINICAL ISOLATES 70
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens 70
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 70
EUCAST Technical Note on voriconazole. 69
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 69
Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors 69
Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study 69
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 68
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. 68
EUCAST technical note on posaconazole. 68
In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. 68
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. 67
Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 67
EUCAST technical note on Amphotericin B 66
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report. 66
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 65
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 65
Anticryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems. 65
Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. 65
Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study 65
Posaconazole prophylaxis in experimental systemic zygomycosis. 64
Comparison of four methods for DNA typing of clinical isolates of Candida glabrata. 64
Caspofungin in combination with amphotericin B against Candida glabrata. 64
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. 64
Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. 64
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. 63
In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. 63
Caspofungin in combination with amphotericin B against Candida parapsilosis. 63
Disruption of homocitrate synthase genes in Candida albicans affects growth but not virulence. 63
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. 62
Voriconazole and multidrug resistance in Candida albicans. 62
Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. 62
Tolerance to amphotericin B in clinical isolates of Candida tropicalis. 62
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. 61
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. 61
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. 61
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. 61
Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. 61
Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients. 60
EUCAST technical note on fluconazole. 60
Efficacy of caspofungin against Aspergillus terreus 60
Totale 7.966
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.295
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.295
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020273 0 0 0 0 0 0 0 0 0 0 34 239
2020/20212.631 148 273 353 48 304 190 253 159 223 283 289 108
2021/20221.519 133 433 13 42 20 63 117 70 76 136 156 260
2022/20232.071 215 172 150 113 135 354 13 96 563 11 176 73
2023/20241.297 214 25 68 240 248 280 26 18 15 14 15 134
2024/20251.804 212 203 166 29 61 60 168 112 609 161 23 0
Totale 11.790